Archive | Hot Mandates RSS feed for this section

Hot Life Science Investor Mandate 1: VC Arm of Larger Fund Looks to Grow in 2013 – January 22, 2013

22 Jan

A fund located in North America with around $200 million in current AUM will grow to $400 million in assets by the end of 2013. The fund is the venture capital arm of a larger fund with AUM upward of $50 billion. Over the last 12 months, the group has allocated to more than 10 firms, making the VC number one in its region. The firm is currently looking for new opportunities in the life science space within the next 6-9 months. They typically allocate anywhere between $500,000 and $50 million per firm. The group is a lifecycle investor, which allows them to deploy capital throughout a firm’s entire financing lifecycle, and thus participate in every round of financing.

The firm is currently looking for companies in the information provider space, and is particularly interested in healthcare IT firms. The firm has a global investment mandate, but prefers North American targets for allocation.

The firm almost entirely invests in companies that are pre-revenue, but will consider companies that are not cash-flow-positive. The fund will consider firms with products on the market on a discretionary basis, but has no strict requirements in terms of their EBITDA or annual revenue.

Tags: , , , , , , , , ,

Hot Life Science Investor Mandate 2: Large Family Office Looking for Opportunities in Medtech Subsectors – January 22, 2013

22 Jan

A family office located in the Western US with around $100 million in assets is looking for a compelling opportunity for allocation within the next 6-9 months. The office invested in more than five deals in 2012, typically between $1-5 million per firm.

The foundation is most interested in medical devices, and will look at firms within the full gamut of medtech subsectors. Typically, the office allocates to firms that have at least one product on the market. They have no strict criteria in terms of a firm’s EBITDA or revenue, but require that any firm in which they invest has goals to lower the cost of healthcare.

Tags: , , , , , ,

Hot Life Science Investor Mandate 3: Generalist PE Fund Interested in CRO’s, CMO’s – January 22, 2013

22 Jan

A private equity fund located in the Central US with roughly $1 billion under management intends to make allocations in the tens of millions on a case-by-case basis over the first half of 2013. The firm is generalist and invests across sectors, but has a specific interest in life sciences & medical technologies. Within this space, the firm is opportunistic in almost every aspect, but does require that an issuer be EBITDA-positive. This means that a firm must have at least one product on the market generating revenue to be of interest. Though the firm has looked at and invested in therapeutics and medtech companies historically, a primary interest currently is service providers such as CROs and CMOs.

Tags: , , , , , , ,

Hot Life Science Investor Mandate 1: PE Group with AUM Over $1b Plans to Grow in 2013 – January 15, 2013

15 Jan

A private equity group headquartered in the US is currently deploying assets from their most recent fund, which closed at nearly $400 million, bringing the firm’s total assets under management to over $1 billion. The group, which also has offices in China, has been very actively seeking and investing in new companies in the life sciences space, and still has a great deal of dry powder on hand from their latest close. They have made several new investments within the last two months, and anticipate that they will be investing at around the same pace throughout 2013 if compelling opportunities continue to arise. The firm typically allocates in the millions of dollars, but has written tickets up to $50 million in the past.

The firm is interested in biotech firms creating therapeutics, medical technology companies that develop medical devices, and specialty pharmaceutical companies. In the biotech therapeutics and diagnostics space, the firm is opportunistic in terms the indication of a product that a firm is targeting, and is especially interested in firms that are developing drugs for the treatment of orphan diseases.

Tags: , , ,

Hot Life Science Investor Mandate 2: NPO Looking for Biotechs Developing Brain Disorder Therapeutics – January 15, 2013

15 Jan

A non-profit based in the Western US with nearly $50 million in assets is interested in biotech firms developing therapeutics that target brain disorders. The firm typically allocates from the hundreds of thousands into the millions per firm, and is looking to allocate to one more firm in the life science’s space for their second fund. They are especially interested in technologies that are able to deliver therapeutics across the blood brain barrier, as well as the personalized medicine space. The firm prefers funds that are in between phase I and phase II of the clinical development process, but will consider products in preclinical, phase I, and phase II development.

Tags: , , ,

Hot Life Science Investor Mandate 3: Government Organization Seeks Large-Scale Biotech – January 15, 2013

15 Jan

A not-for-profit government organization headquartered in Canada is currently looking for new projects in the life sciences space for their allocation round in the spring of 2013. The organization was granted investment funds through the Canadian government to promote research and advancement in the life science sector. The firm typically allocates from $1 million and into the tens of millions per project. They are looking for large-scale projects in the biotech R&D space that are developing products based on genomics.

Tags: , , ,

Hot Life Science Investor Mandate 1: Large State Fund Seeking Medical Device Suppliers, Engineering for Allocation – January 8, 2013

7 Jan

A fund in the Southern United States, backed by capital from its state government, is currently seeking new investment opportunities in the life sciences space. The fund, which has nearly $500 million under management, was created in order to attract start up companies, as well as the best researchers and scientists, to its home state. More than half of the fund’s investments are in the life sciences space, and since 2005, it has dedicated close to $1 billion to the sector. The fund typically invests in 10-20 companies a year, and their allocation size ranges from $100,000 into the millions of dollars. They are specifically interested in suppliers and engineering in the medical device space, but also has interest in the biotech therapeutics & diagnostics, and biotech R&D services. In terms of biotech therapeutics and diagnostics firms, the fund is fairly opportunistic in terms of subsector and indication. The firm is generally agnostic in terms of a product’s development phase, and will therefore consider pre-revenue firms, as well as firms that have products on the market.

Tags: , , ,

← Older Entries
Newer Entries →